

02-19-04



PHA 4174.4 (3480/3)
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Brown et al.

Serial No. 10/734,829

Filed December 12, 2003

For FLUORO-SUBSTITUTED BENZENESULFONYL COMPOUNDS FOR THE
TREATMENT OF INFLAMMATION

February 18, 2004

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VIRGINIA 22313-1450

SIR:

INFORMATION DISCLOSURE STATEMENT

* In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the
duty of disclosure set forth in 37 C.F.R. 1.56, applicants submit the attached PTO/SB/08A for
consideration by the Patent and Trademark Office in the above-entitled application and to be
made of record therein.

The references listed on the attached PTO/SB/08A have been previously submitted in
parent application Serial No. 10/319,916 and, therefore, in accordance with MPEP 609, are not
being provided at this time.

This Information Disclosure Statement is being submitted pursuant to 37 C.F.R. §1.97(b)
in that applicants believe that it is being filed prior to the mailing date of the first Office action
on the merits. Accordingly, neither a statement nor fee under 37 C.F.R. §1.97(c) or (d) is
required. However, if an Office action was issued prior to the date of mailing of this Information
Disclosure Statement, the Commissioner is hereby authorized to charge any required fees
regarding this Information Disclosure Statement to Deposit Account No. 19-1345.

Respectfully submitted,

Patricia K. Fitzsimmons, Reg. No. 52,894
SENNIGER, POWERS, LEAVITT & ROEDEL
One Metropolitan Square, 16th Floor
St. Louis, Missouri 63102
(314) 231-5400


PKF/kll

Express Mail Label No. EL 998651396 US

PTO/SB/08A

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)


Complete if Known

Application Number	10/734,829
Filing Date	December 12, 2003
Confirmation Number	not yet assigned
First Named Inventor	Brown et al.
Group Art Unit	not yet assigned
Examiner	not yet assigned
Attorney Docket No.	PHA 4174.4 (3480/3)

Sheet

1

of

8

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
	1	4,146,721	B1	Rainer	03-27-1979
	2	4,822,805	B1	Takasugi et al.	04-18-1989
	3	4,914,121	B1	Sawai et al.	04-03-1990
	4	5,051,518	B1	Murray et al.	09-24-1991
	5	5,134,142	B1	Matsuo et al.	07-28-1992
	6	5,338,749	B1	Wuest et al.	08-16-1994
	7	5,344,991	B1	Reitz et al.	09-06-1994
	8	5,380,738	B1	Norman et al.	01-10-1995
	9	5,387,592	B1	Bradbury et al.	02-07-1995
	10	5,389,635	B1	Olson	02-14-1995
	11	5,393,790	B1	Reitz et al.	02-28-1995
	12	5,401,765	B1	Lee	03-28-1995
	13	5,418,254	B1	Huang et al.	05-23-1995
	14	5,420,287	B1	Reitz et al.	05-30-1995
	15	5,434,178	B1	Talley et al.	07-18-1995
	16	5,466,823	B1	Talley et al.	11-14-1995

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/734,829
				Filing Date	December 12, 2003
				Confirmation Number	not yet assigned
				First Named Inventor	Brown et al.
				Group Art Unit	not yet assigned
				Examiner	not yet assigned
Sheet	2	of	8	Attorney Docket No.	PHA 4174.4 (3480/3)

	17	5,475,018	B1	Lee et al.	12-12-1995
	18	5,486,534	B1	Lee et al.	01-23-1996
	19	5,504,215	B1	Talley et al.	04-02-1996
	20	5,508,426	B1	Talley et al.	04-16-1996
	21	5,510,496	B1	Talley et al.	04-23-1996
	22	5,516,907	B1	Talley et al.	05-14-1996
	23	5,521,193	B1	Flynn et al.	05-28-1996
	24	5,521,207	B1	Graneto	05-28-1996
	25	5,534,521	B1	Flynn et al.	07-09-1996
	26	5,565,482	B1	Talley et al.	10-15-1996
	27	5,576,339	B1	Huang et al.	11-19-1996
	28	5,596,008	B1	Lee	01-21-1997
	29	5,616,601	B1	Khanna et al.	04-01-1997
	30	5,639,777	B1	Lee	06-17-1997
	31	5,663,180	B1	Reitz et al.	09-02-1997
	32	5,668,161	B1	Talley et al.	09-16-1997
	33	5,670,510	B1	Huang et al.	09-23-1997
	34	5,672,626	B1	Huang et al.	09-30-1997
	35	5,672,627	B1	Huang et al.	09-30-1997
	36	5,719,163	B1	Norman et al.	02-17-1998

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/734,829
				Filing Date	December 12, 2003
				Confirmation Number	not yet assigned
				First Named Inventor	Brown et al.
				Group Art Unit	not yet assigned
				Examiner	not yet assigned
Sheet	3	of	8	Attorney Docket No.	PHA 4174.4 (3480/3)

	37	5,736,579	B1	Reitz et al.	04-07-1998
	38	5,739,166	B1	Reitz et al.	04-14-1998
	39	5,756,529	B1	Isakson et al.	05-26-1998
	40	5,760,068	B1	Talley et al.	06-02-1998
	41	5,859,036	B1	Sartori et al.	01-12-1999
	42	5,859,257	B1	Talley	01-12-1999
	43	5,886,016	B1	Talley et al.	03-23-1999
	44	5,908,852	B1	Talley et al.	06-01-1999
	45	5,916,905	B1	Weier et al.	06-29-1999
	46	5,932,598	B1	Talley et al.	08-03-1999
	47	5,935,990	B1	Khanna et al.	08-10-1999
	48	5,994,381	B1	Haruta et al.	11-30-1999

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office	Number ⁴	Kind Code ² (if known)			
	49	EP	26928	A1	CDC Life Sciences Inc.	04-15-1981	
	50	EP	197704	A2	GEC Avionics Limited	10-15-1986	
	51	EP	372445	B1	The Du Pont Merck Pharmaceutical Company	06-13-1990	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/734,829
				Filing Date	December 12, 2003
				Confirmation Number	not yet assigned
				First Named Inventor	Brown et al.
				Group Art Unit	not yet assigned
				Examiner	not yet assigned
Sheet	4	of	8	Attorney Docket No.	PHA 4174.4 (3480/3)

	52	EP	418845	A1	Fujisawa Pharmaceutical	03-27-1991	
	53	EP	745596	A1	Japan Tobacco, Inc.	12-04-1996	
	54	EP	799823	A1	Sankyo Company Limited	10-08-1997	
	55	EP	1064964	A2	Pfizer Products Inc.	01-03-2001	
	56	GB	2294879	A	Merck & Co Inc.	05-15-1996	
	57	JP	1045374	A	Kokusai Shiyaku KK (abstract)	02-17-1989	
	58	JP	4277724	A	Sumitomo Electric Ind. Ltd. (abstract)	10-02-1992	
	59	JP	5323522	A	Fuji Photo Film Co Ltd. (abstract)	12-07-1993	
	60	WO	92/05162	A1	Taiho Pharmaceutical Co., Ltd.	04-02-1992	
	61	WO	92/19604	A1	Taiho Pharmaceutical Co., Ltd.	11-12-1992	
	62	WO	93/14082	A1	Smith-Kline Beecham Corporation	07-22-1993	
	63	WO	94/13635	A1	Merck Frosst Canada Inc.	06-23-1994	
	64	WO	94/15932	A1	G.D. Searle & Co.	07-21-1994	
	65	WO	94/20480	A1	Merck Frosst Canada Inc.	09-15-1994	
	66	WO	94/26731	A1	Merck Frosst Canada Inc.	11-24-1994	
	67	WO	95/00501	A2	Merck Frosst Canada Inc.	01-05-1995	
	68	WO	95/30652	A1	G.D. Searle & Co.	11-16-1995	
	69	WO	95/30656	A1	G.D. Searle & Co.	11-16-1995	
	70	WO	96/03387	A1	G.D. Searle & Co.	02-08-1996	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/734,829
				Filing Date	December 12, 2003
				Confirmation Number	not yet assigned
				First Named Inventor	Brown et al.
				Group Art Unit	not yet assigned
				Examiner	not yet assigned
Sheet	5	of	8	Attorney Docket No.	PHA 4174.4 (3480/3)

	71	WO	96/03388	A1	G.D. Searle & Co.	02-08-1996	
	72	WO	96/09293	A1	G.D. Searle & Co.	03-28-1996	
	73	WO	96/19462	A1	Japan Tobacco Inc. (abstract)	06-27-1996	
	74	WO	96/19463	A1	Japan Tobacco Inc. (abstract)	06-27-1996	
	75	WO	96/36617	A1	G.D. Searle & Co.	11-21-1996	
	76	WO	96/37467	A1	Merck Frosst Canada Inc.	11-28-1996	
	77	WO	97/16435	A1	Merck Frosst Canada Inc.	05-09-1997	
	78	WO	97/25045	A1	SmithKline Beecham Corporation	07-17-1997	
	79	WO	97/25047	A1	SmithKline Beecham Corporation	07-17-1997	
	80	WO	97/25048	A1	SmithKline Beecham Corporation	07-17-1997	
	81	WO	98/03484	A1	Merck Frosst Canada Inc.	01-29-1998	
	82	WO	98/07425	A1	SmithKline Beecham Corporation	02-26-1998	
	83	WO	98/11080	A1	Laboratories UPISA	03-19-1998	
	84	WO	98/22442	A1	Angelini Recherche S.p.A. Societa Consatile	05-28-1998	
	85	WO	98/47890	A1	G.D. Searle & Co.	10-29-1998	
	86	WO	99/14205	A1	Almirall Prodesfarma SA	03-25-1999	
	87	WO	99/64415	A1	Pfizer Inc.	12-16-1999	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/734,829
				Filing Date	December 12, 2003
				Confirmation Number	not yet assigned
				First Named Inventor	Brown et al.
				Group Art Unit	not yet assigned
				Examiner	not yet assigned
Sheet	6	of	8	Attorney Docket No.	PHA 4174.4 (3480/3)

OTHER ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶	
	88	AHLUWALIA et al., "Mechanism of the Debromination in Heteocyclization Using α,α -Dibromocarbonyl Compounds as Synthons." Synth. Commun., 1989, pp. 619-626, Vol. 19, Nos. 3&4.		
	89	BAGETTA et al., "HIV-1 gp120-Induced Apoptosis in the Rat Neocortex Involves Enhanced Expression of Cyclo-Oxygenase Type 2 (Cox-2)." Biochem. Biophys. Res. Commun., 1998, pp. 819-824, Vol. 244.		
	90	BARNES et al., "Cyclooxygenase-2 Expression in Airway Cells." Lung Biol. Health Dis, 1998, pp. 111-127, Vol. 114.		
	91	BOSCH et al., "Efficacy and Tolerability of Intramuscular and Oral Meloxicam in Patients with Acute Lumbago: A Comparison with Intramuscular and Oral Piroxicam." Curr. Med. Res. Opin., 1997, pp 29-38, Vol. 14, No. 1.		
	92	BUCKMAN et al., "Cox-2 Expression in Induced by UVB Exposure in Human Skin: Implications for the development of skin cancer." Carcinogenesis, 1998, pp. 723-729, Vol. 19, No. 5.		
	93	BUSTOS et al., "Modulation of Eicosanoid Metabolism in Endothelial Cells in a Xenograft Model." J. Clin. Invest., 1997, pp 1150-1158, Vol. 100, No. 5.		
	94	CHU et al., "Synthesis of Sodium androst-5-ene-17-one-3 β -methylene sulfonate." Steroids, 1997, pp 543-545, Vol. 62.		
	95	DIKSHIT et al., "Synthesis and biological activity of 2,3- and 3,4-diarylfurans and 2,3,4-triaryl-2,5-dihydrofurans." Indian J. Chem, Sect. B, 1990, pp 954-960, Vol. 29B, No. 10.		
	96	DOROFEENKO et al., Khim. Farm. Zh., 1982, pp. 920-921, Vol. 16.		
	97	FAID-ALLAH et al., "Pyrazole Derivatives with Possible Hypoglycemic Activity." Ind. J. Chem., Sect. B, 1988, pp. 245-249, Vol. 27B, No. 3.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/734,829
				Filing Date	December 12, 2003
				Confirmation Number	not yet assigned
				First Named Inventor	Brown et al.
				Group Art Unit	not yet assigned
				Examiner	not yet assigned
Sheet	7	of	8	Attorney Docket No.	PHA 4174.4 (3480/3)

	98	GIERSE et al., "Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase." Biochem J., 1995, pp. 479-484, Vol. 305, Part 2.	
	99	HARGREAVES et al., "A New and Sensitive Method for Measuring thermal Nociception in Cutaneous Hyperalgesia." Pain, 1988, pp. 77-88, Vol. 32.	
	100	HIDA et al., "Non-small Cell Lung Cancer Cyclooxygenase Activity and Proliferation are Inhibited by Non-steroidal Antiinflammatory Drugs." Anticancer Res., 1998, pp. 775-782, Vol. 18, No. 1A.	
	101	HUANG et al., "A Novel One-Pot Conversion of Methyl Sulfones to Sulfonamides." Tetrahedron Letters, 1994, pp. 7201-7204, Vol. 35, No. 39.	
	102	KAWAMORI et al., "Chemopreventive Activity of Celecoxib, a Specific Cyclooxygenase-2 Inhibitor, against Colon Carcinogenesis." Cancer Res., 1998, pp. 409-412, Vol. 58, No. 3.	
	103	KHARASCH et al., "Derivatives of Sulfenic Acids. V. 1-Fluorenone Sulfur Compounds." J. Am. Chem. Soc., 1951, pp. 3240-3244, Vol. 73, No. 7.	
	104	MIYAMOTO et al., "The effect of cyclooxygenase-2 inhibitor on experimental allergic neuritis." Neuro Report, 1998, pp. 2331-2334, Vol. 9, No. 10.	
	105	MIYAURA et al., "The Palladium-Catalyzed Cross-Coupling Reaction of Phenylboronic Acid with Haloarenes in the Presence of Bases." Synth. Commun., 1981, pp. 513-519, Vol. 11, No. 7.	
	106	MUKERJEE et al., "Synthesis of Some Formazans and tetrazolium salts as antiviral agents." Acta. Pharma. Jugosl., 1981, pp. 151-158, Vol. 31.	
	107	NASJLETTI A. "The Role of Eicosanoids in Angiotensin-Dependent Hypertension." Hypertension, 1998, pp. 194-200, Vol. 31, No. 1, Part 2.	
	108	NOGAWA et al., "Interaction between inducible nitric oxide synthase and cyclooxygenase-2 after cerebral ischemia." Proc. Natl. Acad. Sci., 1998, pp. 10966-10971, Vol. 95, No. 18.	
	109	REID et al., "Some New β -Diketones Containing the Trifluoromethyl Group." J. Amer. Chem. Soc., 1950, pp 2948-2952, Vol. 72, No. 7.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/734,829
				Filing Date	December 12, 2003
				Confirmation Number	not yet assigned
				First Named Inventor	Brown et al.
				Group Art Unit	not yet assigned
				Examiner	not yet assigned
Sheet	8	of	8	Attorney Docket No.	PHA 4174.4 (3480/3)

	110	SANDHYA et al., "A light and electron microscopic study of cytoplasmic phospholipase A ₂ and cyclooxygenase-2 in the hippocampus after kainate lesions." <i>Brian Res.</i> , 1998, pp. 223-231, Vol. 788.	
	111	SHOUP et al., "Cyclooxygenase-2 Inhibitor NS-398 Improves Survival and Restores Leukocyte Counts in Burn Infection." <i>J. Trauma: Inj., Infec., Crit Care</i> , 1998, pp 215-221, Vol. 45, No. 2.	
	112	SINGER et al., "Cyclooxygenase 2 Is Induced in Colonic Epithelial Cells in Inflammatory Bowel Disease." <i>Gastroenterology</i> , 1998, pp. 297-306, Vol. 115, No. 2.	
	113	SPEIR et al., "Aspirin Attenuates Cytomegalovirus Infectivity and Gene Expression Mediated by Cyclooxygenase-2 in Coronary Artery Smooth Muscle Cells." <i>Circ. Res.</i> , 1998, pp. 210-216, Vol. 83, No. 2.	
	114	SUBBARAMAIAH et al., "Inhibition of Cyclooxygenase: A Novel Approach to Cancer Prevention (44170)." <i>Proc. Soc. Exp. Biol. Med.</i> , 1997, pp. 201-210, Vol. 216, No. 2.	
	115	TSUJII et al., "Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells." <i>Cell</i> , 1998, pp. 705-716, Vol. 93, No. 5.	
	116	VLEESCHAUWER et al., "Remarkably Mild and Simple Preparations of Sulfinates, Sulfonyl Chlorides and Sulfonamides from Thioanisoles." <i>Syn. Lett.</i> , 1997, pp. 375-377, Vol. 4.	
	117	WILSON et al., "Increased Expression of Inducible Nitric Oxide Synthase and Cyclooxygenase-2 in Barrett's Esophagus and Associated Adenocarcinomas." <i>Cancer Res.</i> , 1998, pp. 2929-2934, Vol. 58, No. 14.	
	118	WINTER et al., "Carrageenin-Induced Edema in Hind Paw of the Rat as an Assay for Antiinflammatory Drugs." <i>Proc. Soc. Exp. Biol. Med.</i> , 1962. pp. 544-547, Vol. 111.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.